Brightpath Biotherapeutics received FDA IND clearance for BP-2202, enabling a first-in-human Phase I trial in patients with relapsed or refractory multiple myeloma. The company said dosing is expected to begin later this year. The clearance extends momentum for early-stage oncology assets reaching human testing and provides a new protocol path for evaluating safety, tolerability, and initial pharmacodynamics in a heavily pretreated disease setting.